A COMBINATION OF TAXOTERE, DOXORUBICIN, CYCLOPHOSPHOMIDE IN ADJUVANT CHEMOTHERAPY OF OPERABLE BREAST CANCER GRANULOCYTE COLONY-STIMULATING FACTORS PRIMARY PROPHYLAXIS

The BCIRG 001 study has shown that a combination of Taxotere, doxorubicin, and cyclophosphomide (TAC regimen) is more effec- tive than the standard FAC (5-fluorouracil, doxorubicin, cyclophosphomide) regimen in adjuvant chemotherapy of operable breast cancer (BC) with mestastases to regional lymph nodes. With higher efficacy, TAC regimen was more toxic: the incidence of febrile neu- tropenia was 24.7%. According to the current EORTC and ASCO guidelines, the use of granulocyte colony-stimulating factors (G-CSF) for primary prophylaxis is indicated when the risk of febrile neutropenia is ≥20%. This study was designed to evaluate the safety of TAC regimen with G-CSF primary prophylaxis in adjuvant chemotherapy (CT) of BC .
Patients with operable BC (T1—3N1M0) and Karnofsky performance status 80% received adjuvant TAC regimen after radical surgery: Taxotere 75 mg/m2, doxorubicin 50 mg/m2, and cyclophosphomide 500 mg/m2. G-CSFs were administered in the standard doses for 5—7 days starting from cycle 1 of CT, for primary prophylaxis of febrile neutropenia.
One hundred and one patients have been treated since 2006. Mean age was 47.5 years (range 25—67 years). Almost half (48.5%) of the patients had Stage IIIa disease, Stages IIa and IIb had 18.8 and 27.7% of patients, respectively.
The tumor was estrogen receptor-positive in 57.4% of the patients and progesterone receptor-positive in 62.4%. Overexpression of Her- 2/neu receptor was documented in 49.5% of cases. The mean number of cycles per patient was 5.8. Ninety-one (90.1%) patients have received a complete course of 6 TAC cycles. The duration of prophylactic use of lenograstim or filgrastim during one CT cycle was 5.9 and 5.6 days, respectively.
Episodes of febrile neutropenia were observed at 19 (3.2%) CT cycles in 9 (8.9%) patients. Neutropenic infections were recorded at 4 (0.78%) cycles in 3 (3%) patients.
Thus, the use of GCSF substantially reduces the incidence of TAC-associated febrile neutropenia and infectious complications and ensures a safe and complete course of effective adjuvant CT for the vast majority (90.1%) of patients. The data presented suggest that there is a need for primary prophylaxis with G-CSF in all BC patients receiving adjuvant TAC.

1. Early Breast Cancer Trialists' Collaborative Group. Polychemotherapy for early breast cancer: an overview of the randomised trials. Lancet 1998;352:30— 942.

2. Early Breast Cancer Trialists' Collaborative Group. Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15- year survival: an overview of the ran- domised trials. Lancet 2005;365:1687— 717.

3. Roche H., Fumoleau P., Spielmann M. et al. Sequential adjuvant epirubicin- based and docetaxel chemotherapy for node-positive breast cancer patients: the FNCLCC PACS 01 trial. J Clin Oncol 2006;24(36):5664—71.

4. Jones S., Holmes F., O'Shaughnessy J. Docetaxel with cyclophosphamide is associated with an overall survival benefit compared with doxorubicin and cyclophosphamide: 7-year follow-up of US Oncology Research Trial 9735. J Clin Oncol 2009;27(8):1177—83.

5. Martin M., Pienkowski T., Mackey J. et al. Adjuvant docetaxel for node-posi- tive breast cancer. N Engl J Med 2005;352:2302—13.

6. Perez E. TAC - a new standard in adjuvant therapy for breast cancer? N Engl J Med 2005;352:2346—8.

7. Bonadonna G., Valagussa P., Moliterni A. et al. Adjuvant cyclophos- phamide, methotrexate, and fluorouracil in node-positive breast cancer: the results of 20 years of follow up. New Engl Med 1995;332:901—6.

8. Chirivella I., Bermejo B., Insa A. et al. Optimal delivery of anthracycline-based chemotherapy in adjuvant setting improves outcome of breast cancer patients. Breast Cancer Res Treat 2008;114(3):479—84.

9. Hryniuk W., Frei E., Wright F.A. et al. A single scale for comparing dose-inten- sity of all chemotherapy regimens in breast cancer: summation of dose intencity. J Clin Oncol 1998;16:3137—47.

10. Aapro M.S., Cameron D.A., Pettengel R. et al. EORTC guidelines for the use of granulocyte-colony stimulating factor to reduce the incidence of chemotherapy-induced febril neutropenia in adult patients with lymphomas and solid tumours. Eur J Cancer 2006;42:2433—53.

11. Martin M., Lluch A., Segur M.A. et al. Toxicity and health-related quality of life in breast cancer patients receiving adjuvant docetaxel, doxorubicin, cyclophosphamide (TAC) or 5-fluorouracil, doxorubicin and cyclophosphamide (FAC): impact of adding primary prophylactic granulocyte- colonystimulating factor to the TAC regi- men. Ann Oncol 2006;17(8):1205—112. Von Minckwitz G., Blohmer J., Loehr A. et al. Pegfilgastrim alone or with ciproflax- in significantly reduces febrile neutropenia and hospitalization vs G-CSF alone in breast cancer patients receiving neoadju- vant chemotherapy with docetaxel/dox- orubicin/cyclophosphamide (TAC). Eur J Cancer 2006;4(Suppl 2):151—2.